Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Clinicopathologic Conference, Oligdendroglioma II/IV with IDH1 R132H mutation and codelation of 1p and 19q
NEJM 375:2381-2389, Case 38-206, 2016
Clinicopathologic Conference, Glioblastonoma, WHO grade IV of IV, with Methylation of the MGMT Promoter
NEJM 366:2112-2120, Case 17-2012, 2012
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Cliniclopath Conf., Granulomatous Amebic Encephalitis Due to Acanthamoeba
NEJM 355:2678-2689, Case 39-2006, 2006
Clinicopath Conf., Primary Diffuse Large-B-Cell Lymphoma of the Brain
NEJM 352:185-194, Case 1-2005, 2005
White Matter Disease Induced by High-Dose Chemotherapy:MR Imaging & Proton Spectroscopy
AJNR 19:217-221, Brown,M.S.,et al, 1998
Treatment of Secondary Progressive Multiple Sclerosis with the Immunomodulator Linomide:Study with Monthly MRI Evaluation
Neurol 47:341-346, Karussis,D.M.,et al, 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996